Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-03-0060PMID 15073098
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation

  2005cited by this paper
• Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study.

  2002cited by this paper
• European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.

  2001cited by this paper
• Mechanism-based pharmacokinetic model for paclitaxel.

  2001cited by this paper
• Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Pharmacokinetic models for the saturable distribution of paclitaxel.

  1999cited by this paper
• Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

  1999cited by this paper
• Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

  1997cited by this paper
• Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

  1996cited by this paper
• Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• Taxanes: a new class of antitumor agents.

  1995cited by this paper
• Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

  1995cited by this paper
• Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

  1995influential reference
• European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

  1994cited by this paper
• High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma.

  1993cited by this paper
• Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

  1993cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper
• © 1999 Cancer Research Campaign Article no. bjoc.1999.0696

  year unknowncited by this paper

• Mathematical Oncology: How Modeling Is Transforming Clinical Decision Making.

  2025cites this paper
• A smartphone-based portable electrochemical sensor enabled ultrasensitive detection of paclitaxel in serum and injection samples

  2025cites this paper
• From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology

  2025influential citation
• Model-informed precision dosing: State of the art and future perspectives.

  2024cites this paper
• Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.

  2024cites this paper
• Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa

  2023cites this paper
• Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration

  2023cites this paper
• Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice

  2023cites this paper
• Effect of turmeric supplementation on the pharmacokinetics of paclitaxel in breast cancer patients: A study with population pharmacokinetics approach

  2022cites this paper
• Translational Gap in Lung Cancer Research

  2022cites this paper
• Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables

  2020cites this paper
• Role of TDM‐based dose adjustments for taxane anticancer drugs

  2020influential citation
• Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

  2018cites this paper
• Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.

  2017cites this paper
• Individualizing Dosage Regimens of Antineoplastic Agents

  2017cites this paper
• Treatment regimens of classical and newer taxanes

  2016cites this paper
• How I treat hepatitis C virus infection in patients with hematologic malignancies.

  2016cites this paper
• Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy

  2016cites this paper
• Correlation between paclitaxel Tc > 0.05 and its therapeutic efficacy and severe toxicities in ovarian cancer patients

  2016cites this paper
• Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy

  2015cites this paper
• Personalizing chemotherapy dosing using pharmacological methods

  2015cites this paper
• Metabolism of the taxanes including nab-paclitaxel

  2015cites this paper
• Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

  2014cites this paper
• Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

  2013cites this paper
• Development and Evaluation of a Nanoparticle-Based Immunoassay for Determining Paclitaxel Concentrations on Routine Clinical Analyzers

  2013cites this paper
• Pharmacogenetic predictors of taxane-induced peripheral neuropathy

  2013cites this paper
• CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

  2012cites this paper
• A Bayesian Dose-Individualization Method for Warfarin

  2012cites this paper
• Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring

  2012cites this paper
• Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

  2012cites this paper
• Level of evidence for therapeutic drug monitoring of taxanes

  2011cites this paper
• Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

  2011cites this paper
• Niveau de preuve du suivi thérapeutique pharmacologique du paclitaxel

  2010cites this paper
• Therapeutic drug monitoring in cancer chemotherapy.

  2010cites this paper
• [Not Available].

  2010cites this paper
• [Level of evidence for therapeutic drug monitoring for paclitaxel].

  2010cites this paper
• Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

  2009cites this paper
• Pharmacokinetics and tissue distribution of PGG–paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts

  2009cites this paper
• Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization in Clinical Oncology

  2008cites this paper
• Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy

  2008cites this paper
• ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy

  2008cites this paper
• A problem-oriented approach to liver disease in oncology patients

  2008cites this paper
• Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

  2007cites this paper
• Individualized pharmacotherapy with paclitaxel

  2007cites this paper
• Dose-banding of carboplatin: rationale and proposed banding scheme

  2007cites this paper
• Chemotherapy dosing part II: alternative approaches and future prospects.

  2007cites this paper
• Effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) in Combination with Paclitaxel (Taxol) on Prostate Cancer LNCaP Cells Cultured In vitro or Grown as Xenograft Tumors in Immunodeficient Mice

  2006cites this paper
• Real-time Dose Adjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic Cell Transplant: A Bayesian Pharmacokinetic Approach

  2006cites this paper
• Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

  2006cites this paper
• Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors

  2006cites this paper
• Real-time DoseAdjustment of Cyclophosphamide in a Preparative Regimen for Hematopoietic CellTransplant : ABayesian Pharmacokinetic Approach

  2006cites this paper
• Metabolism‐based cyclophosphamide dosing for hematopoietic cell transplant

  2005cites this paper
• Primary prevention with over‐the‐counter statins: A cautionary tale

  2005cites this paper
• Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents

  2004cites this paper